JP2024507139A - 抗菌性化合物 - Google Patents
抗菌性化合物 Download PDFInfo
- Publication number
- JP2024507139A JP2024507139A JP2023548567A JP2023548567A JP2024507139A JP 2024507139 A JP2024507139 A JP 2024507139A JP 2023548567 A JP2023548567 A JP 2023548567A JP 2023548567 A JP2023548567 A JP 2023548567A JP 2024507139 A JP2024507139 A JP 2024507139A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- pharmaceutically acceptable
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148261P | 2021-02-11 | 2021-02-11 | |
| US63/148,261 | 2021-02-11 | ||
| PCT/US2022/015682 WO2022173758A1 (en) | 2021-02-11 | 2022-02-08 | Antibacterial compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507139A true JP2024507139A (ja) | 2024-02-16 |
| JP2024507139A5 JP2024507139A5 (https=) | 2025-02-18 |
Family
ID=82837229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548567A Pending JP2024507139A (ja) | 2021-02-11 | 2022-02-08 | 抗菌性化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240166609A1 (https=) |
| EP (1) | EP4291550A4 (https=) |
| JP (1) | JP2024507139A (https=) |
| CN (1) | CN117279897A (https=) |
| AR (1) | AR124841A1 (https=) |
| TW (1) | TW202246218A (https=) |
| WO (1) | WO2022173758A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019345150A1 (en) * | 2018-09-20 | 2021-05-13 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| TW202322818A (zh) | 2021-09-28 | 2023-06-16 | 美商福吉醫療公司 | Lpxc抑制劑及其用途 |
| TW202417432A (zh) * | 2022-08-10 | 2024-05-01 | 美商布萊克史密斯醫藥公司 | 抗菌化合物 |
| WO2025174875A1 (en) * | 2024-02-13 | 2025-08-21 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| WO2025174868A1 (en) * | 2024-02-13 | 2025-08-21 | Blacksmith Medicines, Inc. | Antibacterial compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013100277A (ja) * | 2011-10-19 | 2013-05-23 | Taisho Pharmaceutical Co Ltd | 新規なヒドロキサム酸誘導体を含有する医薬 |
| WO2018216822A1 (en) * | 2017-05-25 | 2018-11-29 | Taisho Pharmaceutical Co., Ltd. | Novel imidazole derivatives |
| WO2020105660A1 (ja) * | 2018-11-21 | 2020-05-28 | 大正製薬株式会社 | 新規イミダゾール誘導体 |
| JP2024507140A (ja) * | 2021-02-11 | 2024-02-16 | ブラックスミス メディシンズ，インク． | 抗菌性化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3180749B2 (ja) | 1997-12-26 | 2001-06-25 | ダイソー株式会社 | ３−ヒドロキシ−γ−ブチロラクトン誘導体の新規製法 |
| WO2008027466A1 (en) * | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
| WO2015085238A1 (en) * | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| DK3233843T3 (da) * | 2014-12-16 | 2019-11-18 | Novartis Ag | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere |
| WO2018208987A2 (en) * | 2017-05-10 | 2018-11-15 | Forge Therapeutics, Inc. | Antibacterial compounds |
| WO2020102572A1 (en) | 2018-11-14 | 2020-05-22 | Forge Therapeutics, Inc. | Antibacterial compounds |
-
2022
- 2022-02-08 EP EP22753215.7A patent/EP4291550A4/en active Pending
- 2022-02-08 CN CN202280027718.2A patent/CN117279897A/zh active Pending
- 2022-02-08 US US18/264,838 patent/US20240166609A1/en active Pending
- 2022-02-08 TW TW111104618A patent/TW202246218A/zh unknown
- 2022-02-08 WO PCT/US2022/015682 patent/WO2022173758A1/en not_active Ceased
- 2022-02-08 JP JP2023548567A patent/JP2024507139A/ja active Pending
- 2022-02-08 AR ARP220100257A patent/AR124841A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013100277A (ja) * | 2011-10-19 | 2013-05-23 | Taisho Pharmaceutical Co Ltd | 新規なヒドロキサム酸誘導体を含有する医薬 |
| WO2018216822A1 (en) * | 2017-05-25 | 2018-11-29 | Taisho Pharmaceutical Co., Ltd. | Novel imidazole derivatives |
| WO2020105660A1 (ja) * | 2018-11-21 | 2020-05-28 | 大正製薬株式会社 | 新規イミダゾール誘導体 |
| JP2024507140A (ja) * | 2021-02-11 | 2024-02-16 | ブラックスミス メディシンズ，インク． | 抗菌性化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022173758A1 (en) | 2022-08-18 |
| AR124841A1 (es) | 2023-05-10 |
| CN117279897A (zh) | 2023-12-22 |
| EP4291550A1 (en) | 2023-12-20 |
| US20240166609A1 (en) | 2024-05-23 |
| EP4291550A4 (en) | 2025-01-22 |
| TW202246218A (zh) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507139A (ja) | 抗菌性化合物 | |
| TWI843142B (zh) | 用作shp2抑制劑的化合物及其應用 | |
| JP2024507140A (ja) | 抗菌性化合物 | |
| TW201431865A (zh) | 硼酸衍生物及其治療用途 | |
| HUT71247A (en) | Heteroarylaminoalkoxyphenyl-alkanoic acid derivatives, pharmaceutical compositions containing them and process for preparing them | |
| CN112074507B (zh) | 作为抗菌素的化合物 | |
| JP7834746B2 (ja) | ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体 | |
| RS66695B1 (sr) | 2-hidroksicikloalkan-1-karbamoil derivati | |
| JP2025526728A (ja) | 抗菌化合物 | |
| TW202417437A (zh) | 抗菌化合物 | |
| CN106458931A (zh) | 抗菌的喹唑啉‑4(3h)‑酮衍生物 | |
| CN112996505A (zh) | 新型咪唑衍生物 | |
| CN116806219A (zh) | 羟基杂环烷-氨甲酰基衍生物 | |
| WO2015027963A1 (zh) | 芳环类衍生物、其药物组合物及其应用 | |
| US20240376054A1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| JP2024536864A (ja) | Ｌｐｘｃ阻害剤およびその使用 | |
| HK40097877A (zh) | 抗菌化合物 | |
| HK40097874A (zh) | 抗菌化合物 | |
| JP2007522181A (ja) | シクロオキシゲナーゼ−１及びシクロオキシゲナーゼ−２阻害剤としての置換アゼチジン化合物、ならびにそれらの調製、および薬剤としての使用 | |
| WO2017198159A1 (zh) | 含桥环的咪唑衍生物 | |
| HK40119559A (zh) | 用於治疗与lpa受体活性相关的病症的化合物和组合物 | |
| WO2025171183A1 (en) | Imidazole containing compounds, derivatives therefore, and uses thereof | |
| CN119923396A (zh) | 芳香乙炔类衍生物及其制备方法和其医药上的用途 | |
| CN118359601A (zh) | 芳香乙炔类衍生物及其制备方法和用途 | |
| CN114075140A (zh) | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260209 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260422 |